Markets closed

DexCom, Inc.

DXCM · Nasdaq

Analyst Consensus

Buy

21 analysts

$85

Current

—

Low

$93

Average

—

High

Average target implies +9.83% versus the current price.

Analyst Ratings Synthesis

Consensus is Buy across 21 analysts, and the supplied consensus mean price target is $90. The available data do not report low or high targets, so target clustering and the width of the range cannot be established; BNK Invest separately cited an average target of $86.11, which the shares briefly exceeded. No named analyst is identified as the most or least bullish, and no attributable rating or target revisions are explicitly reported during the week. The substantive disagreement is therefore only partly visible: bullish commentary points to the earnings beat, stronger 2026 guidance, reimbursement expansion and share gains, while the valuation concern is that the stock has moved above the cited average target. The evidence does not support a more precise analyst split.

Rating Actions

No individual rating actions have been captured for DXCMyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

BTIG

CANACCORD GENUI

CITIGROUP

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MORGAN STANLEY

OPPENHEIMER HLD

PIPER SANDLER

RAYMOND JAMES

SANFORD BERNSTE

STIFEL NICOLAUS

TD COWEN

UBS

WELLS FARGO SEC

WILLIAM BLAIR

WOLFE RESEARCH

ZACKS RESEARCH

Symbol: DXCM
Type: Stock
Sector: Health Care
Industry: Surgical & Medical Instruments & Apparatus
Exchange: Nasdaq

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Key Issues

Bullish view

Q2 revenue grew 13% year over year, while broader reimbursement access and share gains supported demand. The earnings beat and stronger 2026 guidance indicate that adoption may continue to outpace prior expectations.

Bearish view

The stock’s sharp post-earnings advance has already carried it above the cited average analyst target of $86.11. That valuation response leaves less room for further upside if growth or guidance does not continue improving.

Analyst Consensus

See all

Buy

21 analysts

$85

Current

—

Low

$93

Average

—

High

Average target implies +9.83% versus the current price.

Earnings History

BeatMissNo estimate

DexCom, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers